

1 **Single center blind testing of a US multi-center validated diagnostic algorithm for**

2 **Kawasaki disease in Asia**

3 Ho-Chang Kuo<sup>1,\*,<sup>↑</sup></sup>, Shiyong Hao<sup>2,\*</sup>, Bo Jin<sup>3,\*</sup>, C. James Chou<sup>2</sup>, Zhi Han<sup>2</sup>, Ling-Sai  
4 Chang<sup>1</sup>, Ying-Hsien Huang<sup>1</sup>, KuoYuan Hwa<sup>4</sup>, John C. Whitin<sup>2</sup>, Karl G. Sylvester<sup>2</sup>,  
5 Charitha D. Reddy<sup>2</sup>, Henry Chubb<sup>2</sup>, Scott R. Ceresnak<sup>2</sup>, John T. Kanegaye<sup>5</sup>, Adriana H.  
6 Tremoulet<sup>5</sup>, Jane C. Burns<sup>5</sup>, Doff McElhinney<sup>2</sup>, Harvey J. Cohen<sup>2</sup>, Xuefeng B. Ling<sup>2,<sup>↑</sup></sup>

7  
8 <sup>1</sup>Kawasaki Disease Center and Department of Pediatrics, Kaohsiung Chang Gung  
9 Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan  
10 83301

11 <sup>2</sup>School of Medicine, Stanford University, Stanford, CA, 94305, USA

12 <sup>3</sup>mProbe, Inc., Palo Alto, CA 94306, USA

13 <sup>4</sup>Center for Biomedical Industry, Department of Molecular Science and Engineering,  
14 National Taipei University of Technology, Taipei, Taiwan 10608

15 <sup>5</sup>Pediatrics, University of California San Diego, San Diego, CA92093, USA

16 Equal contributions\* as the first author.

17 Corresponding<sup>↑</sup>: [bxling@stanford.edu](mailto:bxling@stanford.edu); [erickuo48@yahoo.com.tw](mailto:erickuo48@yahoo.com.tw).

18 **List of abbreviations**

19 Kawasaki disease: KD

20 Intravenous Immunoglobulin: IVIG

21 American Heart Association: AHA

22 Linear discriminant analysis: LDA

23 White blood cell: WBC

24 C-reactive protein: CRP

25 Gamma glutamyl transferase: GGT

26 Right coronary artery: RCA

27 Left anterior descending: LAD

28 Positive predictive value: PPV

29 Negative positive value: NPV

30 **ABSTRACT**

31 Kawasaki disease (KD) is the leading cause of acquired heart disease in children. A  
32 key objective of research in KD is to reduce the risk of long-term cardiovascular  
33 sequelae by expediting timely diagnosis. The major challenge in KD diagnosis is that it  
34 shares clinical signs with other childhood febrile illnesses. Our previously single-center  
35 developed computer-based two-step algorithm was further tested by a five-center  
36 validation in US. This first blinded multi-center trial validated our approach, with  
37 sufficient sensitivity and positive predictive value, to identify most patients with KD  
38 diagnosed at centers across the US.

39 We sought to determine if our algorithmic approach applied to an Asian cohort. This  
40 study involved 418 KD and 259 febrile controls (FC) from the Chang Gung Memorial  
41 Hospital in Taiwan. Our diagnostic algorithm retained sensitivity (379 of 418; 90.7%),  
42 specificity (223 of 259; 86.1%), PPV (379 of 409; 92.7%), and NPV (223 of 247; 90.3%)  
43 comparable to previous US 2016 single center and US 2020 five center results. Only  
44 4.7% (15 of 418) of KD and 2.3% (6 of 259) of FC patients were identified as  
45 indeterminate. The algorithm identified 18 of 50 (36%) KD patients who presented 2 or 3  
46 principal criteria. Of 418 KD patients, 157 were infants younger than one year and  
47 89.2% (140 of 157) were classified correctly. Of the 44 patients with KD who had  
48 coronary artery abnormalities, our diagnostic algorithm correctly identified 43 (97.7%)  
49 including all patients with dilated coronary artery but one who found to resolve in 8  
50 weeks.

51 We assessed the performance of our KD diagnostic algorithm with a single center Asian  
52 cohort. This work demonstrates the applicability of our algorithmic approach and

53 diagnostic portability, providing evidence to support the launch of an adequately  
54 powered, multicenter study for future Asian application in the emergency department  
55 setting. If deployed in Asia, our tool promises a cost-effective diagnostic approach to  
56 allow the timely management of Asian KD patients even in the absence of KD experts,  
57 to potentially enhance the outcome for KD patients and reduce the risk of coronary  
58 artery aneurysms.

59

60

## 61 INTRODUCTION

62 Kawasaki disease (KD) is an acute vasculitis that affects infants and children and is the  
63 leading cause of acquired pediatric heart disease in the U.S. and Japan [1]. Timely and  
64 accurately diagnosis of KD is critical, yet there isn't a gold standard diagnostic test for  
65 KD. The classic KD diagnostic criteria [2, 3] adopted by the American Heart Association  
66 (AHA) include fever plus  $\geq 4$  of 5 principal clinical signs, which include rash, conjunctival  
67 injection, extremity changes, oropharyngeal changes, and swollen lymph nodes.

68 However, KD shares these clinical signs with other childhood febrile illnesses, causing  
69 missed or delayed diagnosis in emergency departments (EDs).

70 Among patients ultimately diagnosed with KD, only 4.7% receive the correct diagnosis  
71 at the first medical visit [4]. Delayed diagnosis causes delayed treatment [5] and thus  
72 increases the risk of developing aneurysm, and in some children leads to myocardial  
73 infarction or death [6]. Delayed diagnosis is particularly problematic among patients with  
74 incomplete clinical manifestations of KD (having less than 4 principal clinical signs),  
75 despite supplementary laboratory criteria have been adopted by AHA to identify atypical  
76 KD cases. Furthermore, treatment with intravenous immunoglobulin (IVIG), which can  
77 reduce the incidence of coronary aneurysms and risk of long-term cardiovascular  
78 complications [2, 7], is recommended to be given within 10 days of illness. There is a  
79 critical need for clinicians to timely and accurately differentiate KD from other pediatric  
80 febrile illnesses.

81 We have explored to apply an algorithmic approach to the bedside electronic health  
82 record (EHR) datasets, developing predictive analytics [8-37] to drive translational  
83 medicine for improved diagnosis of high impact diseases and prediction of clinical

84 resource utilization. Regarding KD, in 2013, we tested the hypothesis whether statistical  
85 learning on clinical and laboratory test patterns can lead to a single-step algorithm for  
86 KD diagnosis [10]. Combining both clinical and laboratory test results, the algorithm  
87 diagnosed with sensitivity of 74.3% and specificity of 62.8% with > 95% PPV and > 95%  
88 NPV. In 2016, we improved and validated a two-step algorithm to classify an individual  
89 as a patient with KD, a febrile control (FC) or intermediate [21]. In the single-center  
90 validation, the algorithm yielded a sensitivity of 96.0% and a specificity of 78.5% with >  
91 95% PPV and > 95% NPV. We subsequently set to validate this two-step diagnostic  
92 algorithm with five pediatric hospitals in the USA [31]: Boston Children's Hospital,  
93 Boston, Massachusetts; Children's Hospital Colorado, Aurora, Colorado; Children's  
94 Hospital of Orange County, Orange, California; Nationwide Children's Hospital,  
95 Columbus, Ohio; and Rady Children's Hospital, San Diego, California. The blinded US  
96 multicenter validation validates the algorithm with a sensitivity of 91.6%, specificity of  
97 57.8% and PPV and NPV of 95.4% and 93.1%, respectively. The algorithm also  
98 correctly identified 94.0% of KD patients with abnormal echocardiograms.

99 In this study, we performed a blinded, single center validation of this KD diagnostic  
100 algorithm in Taiwan. Validating the algorithmic portability from US to a single center in  
101 Asia, we set to evaluate this algorithm in a prospective multi-center trial in Asia.

## 102 **MATERIAL AND METHODS**

### 103 **Study design**

104 We previously developed and validated, with data from a US single center, a two-step  
105 algorithm that applies a linear discriminant analysis (LDA)-based model followed by a

106 random forest-based algorithm to differentiate patients with KD from children with other  
107 febrile controls (FCs) [8, 10, 21, 31]. Patients who are classified as indeterminate by the  
108 LDA-based model are then evaluated by the random-forest algorithm based on the  
109 number of KD clinical criteria with which they present. In line with previous approach [8,  
110 10, 21, 31], we applied the two-step algorithm, constructed with a single-center US  
111 cohort (Rady Children's Hospital, San Diego, California, the validation cohort in 2016  
112 study [21]), to a single center in Taiwan. The evaluation was blinded to diagnosis during  
113 classification, and then unblinded to calculate performance.

#### 114 **Study population**

115 A single center (Chang Gung Memorial Hospital in Taiwan) cohort of patients with acute  
116 KD were prospectively enrolled by local KD specialists. Signed consent or assent forms  
117 were obtained from the parents of all subjects and from all subjects >6 years of age.  
118 The study was approved by the institutional review boards of the Chang Gung Memorial  
119 Hospital and Stanford University. The diagnosis of KD was made by Taiwan KD  
120 specialists on the 2004 USA AHA guidelines [3]. All FCs had unexplained fever,  $\geq 1$  of  
121 the five principal clinical criteria for KD, and laboratory evaluation. All FC diagnosis was  
122 determined by clinical features, culture or PCR testing. All patients had fever ( $\geq 38.0^\circ$   
123 C) for no more than 10 days and had complete information for nine clinical or laboratory  
124 data points, including the five principal clinical criteria (illness days (ie, days of fever),  
125 total white cell count (WCC), percentage of eosinophils and hemoglobin concentration),  
126 percentages of monocytes, lymphocytes, neutrophils and immature neutrophils (bands),  
127 platelet count, levels of C reactive protein, (CRP), gamma glutamyl transferase (GGT),  
128 alanine aminotransferase (ALT) and erythrocyte sedimentation rate (ESR), gamma

129 glutamyl transferase (GGT), were collected if available. The clinical parameters of  
130 bands, GGT, and ESR were not routinely collected in the Taiwan Chang Gung Hospital  
131 for the KD and FC patients, therefore, not used in the two-step algorithm. Age and sex  
132 for all patients, and coronary artery status and Z-score (SD from the mean adjusted for  
133 body surface area) for patients with KD, were also recorded when available. Coronary  
134 artery status was classified as normal (right coronary artery (RCA) and left anterior  
135 descending (LAD) Z-score always  $<2.5$ ) or abnormal (RCA and/or LAD Z-score  $\geq 2.5$   
136 within the first 6 weeks after diagnosis).

### 137 **Two-step algorithm for differentiation of KD and FCs**

138 The two-step algorithm uses an LDA-based analysis followed by a random forest-based  
139 algorithm as previously described [8, 21, 31]. In this study, input variables of the LDA  
140 model are illness days, the 5 principal clinical criteria and 10 laboratory test variables.  
141 The variables and their corresponding weights in the algorithm are listed in  
142 Supplementary Table 1. One or more variables had missing values for 227 of 418  
143 (54.3%) patients with KD and 256 of 259 (98.8%) FCs. The algorithm was less sensitive  
144 in identifying KD patients with 1 or more missing variables as compared to patients with  
145 complete data. Values were imputed with a k-nearest neighbor algorithm. The output of  
146 the LDA classifies each individual patient as KD, FC or indeterminate. The cut-off  
147 thresholds between the three categories were set in the original US single center  
148 algorithm to provide a positive predictive value (PPV) or negative positive value (NPV)  
149 of 95%. The indeterminate patients were divided into four sub cohorts based on the  
150 number of KD criteria present at the time of diagnosis, and separate random forest

151 models were applied to the patients in each sub-cohort to further stratify these patients  
152 into KD, FC or indeterminate categories [10, 21, 31].

### 153 **Algorithm performance in this Asia single center study**

154 The aim of this study was to analyze the algorithm performance on a single center  
155 Taiwan cohort. We compared the classifications of patients by the algorithm with the  
156 classifications made by the clinical experts who diagnosed these patients. We  
157 calculated sensitivity, specificity, PPV, NPV and rates of indeterminate classification of  
158 the algorithm when applied to this cohort. Performance of the algorithm was evaluated  
159 according to age, illness days and coronary artery status. We also performed  
160 univariable analysis with each of the 15 variables in sub cohorts of patients manifesting  
161  $\leq 2$ , 3 or  $\geq 4$  KD principal clinical criteria. In each sub cohort, the distribution of each  
162 variable was compared between the patients with KD and FCs, and the differences  
163 were measured using Mann-Whitney U test (for continuous variables) or Fisher's exact  
164 test (for categorical variables).

## 165 **RESULTS**

### 166 **Patient characteristics**

167 As shown in Figure 1, 751 patients were enrolled with 462 KD and 289 FC subjects. 26  
168 FC patients were excluded due to incorrect registration of days of fever. 47 patients  
169 (KD: 44; FC: 3) were excluded with days of fever greater than 10 days. One FC patient  
170 was excluded due to the absence of KD principal criteria. For this study, from the  
171 Taiwan single center cohort (Table 1), 418 patients with KD and 259 FCs were used for  
172 the blind testing. Patients with KD were more likely to be male than FCs (60.5% vs

173 53.3%,  $p=0.06$ ). The KDs had a higher median age than the patients with FC (1.3 vs 1.0  
174 years,  $p=0.03$ ). The FCs most common final diagnosis was either bacterial or viral  
175 infection (Table 2).

## 176 **Univariable analysis of clinical and laboratory test variables**

177 The majority of the patients with KD (368 of 418, 88.0%) had 4 or 5 principal clinical  
178 criteria, and 91.3% (217 of 259, 83.7%) of FCs had 1 to 3 principal clinical criteria  
179 (Table 3A). Shown in Figure 2, 36 KD and 59 FC patients had three clinical criteria  
180 while 14 KD and 135 FC had two clinical criteria. 157/418 KD patients were less than 1  
181 year old while 261/418 KD patients were older than 1 year. Most of the laboratory test  
182 variables except C-reactive protein, eosinophils, hemoglobin, and platelet counts  
183 differed significantly between patients with KD and FCs in all 3 sub-cohorts (Table 3B).

## 184 **Asia single center blind test results**

185 In this Taiwan single center study (Figure 3), the algorithm's testing performance is in  
186 line with our 2016 US single center [21] and US 2020 multi-center [31] analyses:  
187 sensitivity of 90.7% (379/418), specificity of 86.1% (223/259), PPV of 92.7% (379/409),  
188 and NPV of 90.3% (223/247); 3.5% (15/418) of the patients with KD and 2.3% (6/259)  
189 FCs were classified as indeterminate. Overall, 5.7% (24/418) of the patients with KD  
190 and 11.5% (30/259) of FCs were misclassified by the algorithm.

191 We stratified the patients into  $< 1$  or  $\geq 1$  year old bins for the performance analysis  
192 (Table 4A, top panel). Of the 157/418 KD infants younger than 1 year, 89.6% were  
193 classified correctly, and 7.0% were indeterminate. Of patients with KD  $\geq 1$  year old,  
194 90.3% were classified correctly, and 8.0% were indeterminate. Shown in Figure 4, for

195 the 379 correctly classified KD, 140/379 were less than 1 year old and 239/379 were  
196 older than 1 year old. For the 24 KD wrongly classified into FC, 10/24 were less than 1  
197 year old and 14/24 were older than 1 year old. For the 15 KD wrongly classified into  
198 intermediate, 7/15 were less than 1 year old and 8/15 were older than 1 year old.

199 We stratified the patients into < 8 or 8-10 illness day bins for the performance analysis  
200 (Table 4B, bottom panel). Of the 327/418 KD patients with < 8 illness days, 93.7% were  
201 classified correctly, and 3.7% were indeterminate. Of the 91/418 KD patients with 8-10  
202 illness days, 95.5% were classified correctly, and 3.3% were indeterminate. Of the  
203 252/259 FC patients with < 8 illness days, 89.1% were classified correctly, and 1.6%  
204 were indeterminate. Of the 7/259 FC patients with 8-10 illness days, 40.0% were  
205 classified correctly, and 28.6% were indeterminate. The poor performance, as  
206 previously observed in US multi-center study [31], the specificity (40.0%) and NPV  
207 (33.3%), of 8-10 illness day FCs may be due to the small sample size (n=7 FCs with 8-  
208 10 illness days). We also compared, the ratio of median laboratory test values between  
209 the KD and FC patients (Table 4B), of the bins of illness day less than 8 or illness day 8-  
210 10. Much more up regulated ratios, of the tests of C-reactive protein, Alanine  
211 aminotransferase and while blood cell, were observed when contrasting between the  
212 bins of illness day less than 8 and illness day 8-10 ( $p$  value < 0.01).

213 There were 50/418 KD patients who presented with 3 or fewer criteria and 368/418 KDs  
214 with 4 or 5 clinical criteria (Figure 5). Compared with its sensitivity in KD patients with 4  
215 or 5 clinical criteria (361/368, 98.0%), the algorithm had a lower sensitivity for KD with  
216 less than or equal to 2 criteria 14.2% (2/14) and for KD with 3 criteria 44.4% (16/36)  
217 (Fisher's exact test  $p$  < 0.0001). Compared with its specificity in FC patients with 4 or 5

218 clinical criteria (10/42, 23.8%), the algorithm had a higher specificity for FC with less  
219 than or equal to 2 criteria 99.4% (157/158) and for FC with 3 criteria 94.9% (56/59)  
220 (Fisher's exact test  $p < 0.0001$ ). For the total of 15 KDs and 6 FCs wrongly classified  
221 into intermediate, 1/13/1 KDs and 1/3/2 FCs were from the bins of with less than or  
222 equal to 2, with 3, or with greater than 4 clinical criteria, respectively.

### 223 **Classification of KD patients with coronary artery abnormalities**

224 Coronary artery abnormalities were documented in 44 of the 418 KD patients (10.5%)  
225 (Table 5). One patient was not classified correctly. The misclassified KD patient had a  
226 maximum Z-score of 2.8 that resolved by 8 weeks after treatment. This is still a  
227 problem, if we use the criteria for treatment. All 8 KDs with aneurysm were identified by  
228 the two-step algorithm.

### 229 **Comparison of clinical and laboratory data between Asian single-center and US** 230 **2016 single-center [21] and 2020 multi-center [31] studies**

231 The frequencies of the five KD principal criteria and illness days in this Taiwan single-  
232 center study were in line with those in the US single-center [21] and multi-center [31]  
233 validation dataset of the algorithm except for cervical lymph node (25.5%/19.5% versus  
234 49.4%), conjunctival injection (44.1%/58.9% versus 19.7%), oropharyngeal changes  
235 (48.4%/46.8% versus 86.1%), and days of illness (5.0/5.0 versus 2.0) in FC subjects  
236 (Table 6).

237

## 238 **DISCUSSION**

239 It is essential to diagnose KD early in the acute phase as early administration with anti-  
240 inflammatory therapies can reduce the risk of developing coronary artery aneurysms [1].  
241 However, the diagnosis of KD remains difficult as the clinical signs overlap with those of  
242 other pediatric febrile illnesses. In this study, we tested a US multi-center validated KD  
243 diagnostic algorithm using a blinded Asian single-center cohort. The algorithm had a  
244 sensitivity of 90.7%, a specificity of 86.1%, a PPV of 92.7%, and a NPV of 90.3%,  
245 similar to that of the US single-center and multi-center validation studies [10, 21, 31].  
246 The algorithm identified 43/44 (98.0%) of patients with KD who developed coronary  
247 artery abnormalities, and only misclassified as one FC patient with Z score (RCA or  
248 LAD)  $\geq 2.5$ , and resolve in 8 weeks. In this study, all 8 KD subjects with aneurysms  
249 were correctly diagnosed by the 2-step algorithm.

250 Given that this algorithm has been validated in US, this blinded Asian single center  
251 study shall provide evidence to support a multi-center prospective testing in an Asian  
252 setting: where the KD prevalence should be higher than US; and in which KD patients  
253 are rare and febrile controls are common to evaluate its potential utility as a physician  
254 support tool.

255 We recognize both strengths and weaknesses in this study. The strength of the study is  
256 the demonstration of the robustness and effectiveness of the algorithm and the  
257 algorithm portability from North America to Asia. The KD and FC subjects in the Asian  
258 single-center are generally younger than the US single-center and multi-center  
259 analyses, thus demonstrating its potential clinical utility across a broad range of similar  
260 appearing illnesses. However, in this Asian study, the clinical parameters of bands,  
261 GGT, and ESR were not routinely collected in the Taiwan Chang Gung Hospital for the

262 KD patients, therefore, not used in the two-step algorithm. If collected in the future, the  
263 algorithm performance might be improved when prediction with Asian patients. The FCs  
264 were not examined by the echocardiography, which may limit our ability to completely  
265 rule out KD diagnosis. In this Asian single-center study, we had a larger number of KD  
266 patients than FCs as in the US multi-center study, and the frequency of KD patients in a  
267 prospective study in the emergency department setting will be much lower, which will  
268 undoubtedly worsen the performance of this algorithm. The actual ratio of KD to FC  
269 patients who would be screened for KD is not known and shall warrant more studies.  
270 We are planning a multi-center study in the Asian emergency room setting to assess the  
271 prevalence of KD and prospectively evaluate the utility of this algorithm.

## 272 **CONCLUSIONS**

273 We assessed the performance of our 2-step algorithm in a blinded, single-center study  
274 in Asia. This work demonstrates the algorithmic portability from North America to Asia,  
275 providing further support for moving forward with an adequately powered, multicenter  
276 study in the Asian emergency department settings to assess if this algorithm will be a  
277 useful clinical support tool to manage Kawasaki disease in Asia where the disease  
278 prevalence is higher than in US.

## 279 **Declaration of interests**

280 We declare no competing interests.

## 281 **Acknowledgement**

282 This research was funded by the following grants CPRPG8H0051-2, CMRPG8L0011  
283 and CMRPG8L1241 provided by Chang Gung Memorial Hospital.

284

285

286 **List of abbreviations**

287 Kawasaki disease: KD

288 Intravenous Immunoglobulin: IVIG

289 American Heart Association: AHA

290 Linear discriminant analysis: LDA

291 White blood cell: WBC

292 C-reactive protein: CRP

293 Gamma glutamyl transferase: GGT

294 Right coronary artery: RCA

295 Left anterior descending: LAD

296 Positive predictive value: PPV

297 Negative positive value: NPV

298

299 **What is already known on this topic**

300 A key objective of research in KD is to reduce the risk of long-term cardiovascular  
301 sequelae by expediting timely diagnosis.

302 The major challenge in diagnosing KD is that it shares clinical signs with other childhood  
303 febrile illnesses.

304 A computer-based algorithm was validated using clinical criteria and laboratory tests to  
305 differentiate US single-center and multi-center patients with KD from those with other  
306 febrile illnesses.

307 **What this study adds**

308 This is the first blinded, single-center testing of a US validated computer algorithm for  
309 the differentiation of patients with KD from others with clinically similar febrile illnesses  
310 in Asia.

311 The algorithm has sufficient sensitivity and PPV to identify the majority of patients with  
312 KD diagnosed at either single center in Asia or centers across North America.

313 The results suggest a promising approach to the timely diagnosis and treatment of KD  
314 patients to reduce the risk of coronary artery aneurysms. The results also provide  
315 evidence to support the launch of the multi-center validation trial in Asia.

316

317 REFERENCE

- 318 1. Burns JC: **New perspectives on Kawasaki disease**. *Arch Dis Child* 2019, **104**(7):616-617.
- 319 2. Newburger JW, Takahashi M, Burns JC, Beiser AS, Chung KJ, Duffy CE, Glode MP, Mason WH,  
320 Reddy V, Sanders SP *et al*: **The treatment of Kawasaki syndrome with intravenous gamma**  
321 **globulin**. *The New England journal of medicine* 1986, **315**:341-347.
- 322 3. Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Tani LY, Burns JC, Shulman ST, Bolger AF,  
323 Ferrieri P, Baltimore RS *et al*: **Diagnosis, treatment, and long-term management of Kawasaki**  
324 **disease: a statement for health professionals from the Committee on Rheumatic Fever,**  
325 **Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American**  
326 **Heart Association**. *Circulation* 2004, **110**:2747-2771.
- 327 4. Anderson MS, Todd JK, Glode MP: **Delayed diagnosis of Kawasaki syndrome: an analysis of the**  
328 **problem**. *Pediatrics* 2005, **115**(4):e428-433.
- 329 5. Daniels LB, Gordon JB, Burns JC: **Kawasaki disease: late cardiovascular sequelae**. *Current*  
330 *opinion in cardiology* 2012, **27**:572-577.
- 331 6. McCrindle BW, Rowley AH, Newburger JW, Burns JC, Bolger AF, Gewitz M, Baker AL, Jackson  
332 MA, Takahashi M, Shah PB *et al*: **Diagnosis, treatment, and long-term management of**  
333 **Kawasaki disease: a scientific statement for health professionals from the American Heart**  
334 **Association**. *Circulation* 2017, **135**(17):e927-e999.
- 335 7. Newburger JW, Takahashi M, Beiser AS, Burns JC, Bastian J, Chung KJ, Colan SD, Duffy CE, Fulton  
336 DR, Glode MP *et al*: **A single intravenous infusion of gamma globulin as compared with four**  
337 **infusions in the treatment of acute Kawasaki syndrome**. *The New England journal of medicine*  
338 1991, **324**:1633-1639.
- 339 8. Ling XB, Lau K, Kanegaye JT, Pan Z, Peng S, Ji J, Liu G, Sato Y, Yu TT, Whitin JC *et al*: **A diagnostic**  
340 **algorithm combining clinical and molecular data distinguishes Kawasaki disease from other**  
341 **febrile illnesses**. *BMC Med* 2011, **9**:130.
- 342 9. Ling XB, Macaubas C, Alexander HC, Wen Q, Chen E, Peng S, Sun Y, Deshpande C, Pan KH, Lin R  
343 *et al*: **Correlation analyses of clinical and molecular findings identify candidate biological**  
344 **pathways in systemic juvenile idiopathic arthritis**. *BMC Med* 2012, **10**:125.
- 345 10. Ling XB, Kanegaye JT, Ji J, Peng S, Sato Y, Tremoulet A, Burns JC, Cohen HJ: **Point-of-care**  
346 **differentiation of Kawasaki disease from other febrile illnesses**. *J Pediatr* 2013, **162**(1):183-188  
347 e183.
- 348 11. Sutherland SM, Ji J, Sheikhi FH, Widen E, Tian L, Alexander SR, Ling XB: **AKI in hospitalized**  
349 **children: epidemiology and clinical associations in a national cohort**. *Clin J Am Soc Nephrol*  
350 2013, **8**(10):1661-1669.
- 351 12. Hao S, Jin B, Shin AY, Zhao Y, Zhu C, Li Z, Hu Z, Fu C, Ji J, Wang Y *et al*: **Risk prediction of**  
352 **emergency department revisit 30 days post discharge: a prospective study**. *PLoS One* 2014,  
353 **9**(11):e112944.
- 354 13. Ji J, Ling XB, Zhao Y, Hu Z, Zheng X, Xu Z, Wen Q, Kastenber ZJ, Li P, Abdullah F *et al*: **A data-**  
355 **driven algorithm integrating clinical and laboratory features for the diagnosis and prognosis of**  
356 **necrotizing enterocolitis**. *PLoS One* 2014, **9**(2):e89860.
- 357 14. Patel CJ, Yang T, Hu Z, Wen Q, Sung J, El-Sayed YY, Cohen H, Gould J, Stevenson DK, Shaw GM *et*  
358 *al*: **Investigation of maternal environmental exposures in association with self-reported**  
359 **preterm birth**. *Reprod Toxicol* 2014, **45**:1-7.
- 360 15. Hao S, Wang Y, Jin B, Shin AY, Zhu C, Huang M, Zheng L, Luo J, Hu Z, Fu C *et al*: **Development,**  
361 **Validation and Deployment of a Real Time 30 Day Hospital Readmission Risk Assessment Tool**  
362 **in the Maine Healthcare Information Exchange**. *PLoS One* 2015, **10**(10):e0140271.

- 363 16. Hu Z, Hao S, Jin B, Shin AY, Zhu C, Huang M, Wang Y, Zheng L, Dai D, Culver DS *et al*: **Online**  
364 **Prediction of Health Care Utilization in the Next Six Months Based on Electronic Health Record**  
365 **Information: A Cohort and Validation Study.** *J Med Internet Res* 2015, **17**(9):e219.
- 366 17. Hu Z, Jin B, Shin AY, Zhu C, Zhao Y, Hao S, Zheng L, Fu C, Wen Q, Ji J *et al*: **Real-time web-based**  
367 **assessment of total population risk of future emergency department utilization: statewide**  
368 **prospective active case finding study.** *Interactive journal of medical research* 2015, **4**(1):e2.
- 369 18. Shin AY, Hu Z, Jin B, Lal S, Rosenthal DN, Efron B, Sharek PJ, Sutherland SM, Cohen HJ,  
370 McElhinney DB *et al*: **Exploring Value in Congenital Heart Disease: An Evaluation of Inpatient**  
371 **Admissions.** *Congenit Heart Dis* 2015, **10**(6):E278-287.
- 372 19. Shin AY, Jin B, Hao S, Hu Z, Sutherland S, McCammond A, Axelrod D, Sharek P, Roth SJ, Ling XB:  
373 **Utility of clinical biomarkers to predict central line-associated bloodstream infections after**  
374 **congenital heart surgery.** *Pediatr Infect Dis J* 2015, **34**(3):251-254.
- 375 20. Tremoulet AH, Dutkowski J, Sato Y, Kanegaye JT, Ling XB, Burns JC: **Novel data-mining approach**  
376 **identifies biomarkers for diagnosis of Kawasaki disease.** *Pediatr Res* 2015, **78**(5):547-553.
- 377 21. Hao S, Jin B, Tan Z, Li Z, Ji J, Hu G, Wang Y, Deng X, Kanegaye JT, Tremoulet AH *et al*: **A**  
378 **classification tool for differentiation of Kawasaki disease from other febrile illnesses.** *J Pediatr*  
379 2016, **176**:114-120 e118.
- 380 22. Jin B, Zhao Y, Hao S, Shin AY, Wang Y, Zhu C, Hu Z, Fu C, Ji J, Wang Y *et al*: **Prospective**  
381 **stratification of patients at risk for emergency department revisit: resource utilization and**  
382 **population management strategy implications.** *BMC Emerg Med* 2016, **16**:10.
- 383 23. Siehr SL, Shi S, Hao S, Hu Z, Jin B, Hanley F, Reddy VM, McElhinney DB, Ling XB, Shin AY:  
384 **Exploring the Role of Polycythemia in Patients With Cyanosis After Palliative Congenital Heart**  
385 **Surgery.** *Pediatr Crit Care Med* 2016, **17**(3):216-222.
- 386 24. Zheng L, Wang Y, Hao S, Shin AY, Jin B, Ngo AD, Jackson-Browne MS, Feller DJ, Fu T, Zhang K *et*  
387 *al*: **Web-based Real-Time Case Finding for the Population Health Management of Patients**  
388 **With Diabetes Mellitus: A Prospective Validation of the Natural Language Processing-Based**  
389 **Algorithm With Statewide Electronic Medical Records.** *JMIR Med Inform* 2016, **4**(4):e37.
- 390 25. Hao S, Fu T, Wu Q, Jin B, Zhu C, Hu Z, Guo Y, Zhang Y, Yu Y, Fouts T *et al*: **Estimating One-Year**  
391 **Risk of Incident Chronic Kidney Disease: Retrospective Development and Validation Study**  
392 **Using Electronic Medical Record Data From the State of Maine.** *JMIR Med Inform* 2017,  
393 **5**(3):e21.
- 394 26. Jin B, Liu R, Hao S, Li Z, Zhu C, Zhou X, Chen P, Fu T, Hu Z, Wu Q *et al*: **Defining and**  
395 **characterizing the critical transition state prior to the type 2 diabetes disease.** *PLoS One* 2017,  
396 **12**(7):e0180937.
- 397 27. Guo Y, Zheng G, Fu T, Hao S, Ye C, Zheng L, Liu M, Xia M, Jin B, Zhu C *et al*: **Assessing Statewide**  
398 **All-Cause Future One-Year Mortality: Prospective Study With Implications for Quality of Life,**  
399 **Resource Utilization, and Medical Futility.** *J Med Internet Res* 2018, **20**(6):e10311.
- 400 28. Ye C, Fu T, Hao S, Zhang Y, Wang O, Jin B, Xia M, Liu M, Zhou X, Wu Q *et al*: **Prediction of**  
401 **Incident Hypertension Within the Next Year: Prospective Study Using Statewide Electronic**  
402 **Health Records and Machine Learning.** *J Med Internet Res* 2018, **20**(1):e22.
- 403 29. Ceresnak SR, Pass RH, Dubin AM, Yang L, Motonaga KS, Hedlin H, Avasarala K, Trela A,  
404 McElhinney DB, Janson C *et al*: **Validation of a novel automated signal analysis tool for ablation**  
405 **of Wolff-Parkinson-White Syndrome.** *PLoS One* 2019, **14**(6):e0217282.
- 406 30. Ye C, Wang O, Liu M, Zheng L, Xia M, Hao S, Jin B, Jin H, Zhu C, Huang CJ *et al*: **A Real-Time Early**  
407 **Warning System for Monitoring Inpatient Mortality Risk: Prospective Study Using Electronic**  
408 **Medical Record Data.** *J Med Internet Res* 2019, **21**(7):e13719.

- 409 31. Hao S, Ling XB, Kanegaye JT, Bainto E, Dominguez SR, Heizer H, Jone PN, Anderson MS, Jaggi P,  
410 Baker A *et al*: **Multicentre validation of a computer-based tool for differentiation of acute**  
411 **Kawasaki disease from clinically similar febrile illnesses**. *Arch Dis Child* 2020, **105**(8):772-777.
- 412 32. Huang J, Zheng L, Li Z, Hao S, Ye F, Chen J, Gans HA, Yao X, Liao J, Wang S *et al*: **Kinetics of SARS-**  
413 **CoV-2 positivity of infected and recovered patients from a single center**. *Sci Rep* 2020,  
414 **10**(1):18629.
- 415 33. Ye C, Li J, Hao S, Liu M, Jin H, Zheng L, Xia M, Jin B, Zhu C, Alfreds ST *et al*: **Identification of elders**  
416 **at higher risk for fall with statewide electronic health records and a machine learning**  
417 **algorithm**. *Int J Med Inform* 2020, **137**:104105.
- 418 34. Zheng L, Wang O, Hao S, Ye C, Liu M, Xia M, Sabo AN, Markovic L, Stearns F, Kanov L *et al*:  
419 **Development of an early-warning system for high-risk patients for suicide attempt using deep**  
420 **learning and electronic health records**. *Transl Psychiatry* 2020, **10**(1):72.
- 421 35. Duong SQ, Zheng L, Xia M, Jin B, Liu M, Li Z, Hao S, Alfreds ST, Sylvester KG, Widen E *et al*:  
422 **Identification of patients at risk of new onset heart failure: Utilizing a large statewide health**  
423 **information exchange to train and validate a risk prediction model**. *PLoS One* 2021,  
424 **16**(12):e0260885.
- 425 36. Stevenson DK, Wong RJ, Aghaeepour N, Maric I, Angst MS, Contrepois K, Darmstadt GL, Druzin  
426 ML, Eisenberg ML, Gaudilliere B *et al*: **Towards personalized medicine in maternal and child**  
427 **health: integrating biologic and social determinants**. *Pediatr Res* 2021, **89**(2):252-258.
- 428 37. Zhang Y, Han Y, Gao P, Mo Y, Hao S, Huang J, Ye F, Li Z, Zheng L, Yao X *et al*: **Electronic Health**  
429 **Record-Based Prediction of 1-Year Risk of Incident Cardiac Dysrhythmia: Prospective Case-**  
430 **Finding Algorithm Development and Validation Study**. *JMIR Med Inform* 2021, **9**(2):e23606.

431




Figure 1. Cohort construction of patients in Chang Gung Cohort





Figure 2. (Left) Percentage of KD and FC patients with 2 or 3 principal clinical KD criteria; (Right) percentage of KD patients with age of either <1 or ≥ 1 year old. FC, febrile control; KD, Kawasaki disease.




Figure 3. Performance of the two-step algorithm for classification of patients with KD and FCs. Left: a 2x2 table compared with US single-center validation results. The US cohort was described in 2016 Hao et al. publication. Right: percentages of correctly classified, misclassified and indeterminate patients. FCs, febrile controls; KD, Kawasaki disease; NPV, negative positive value; PPV, positive predictive value.




Figure 4 Percentage of KD patients, (left) correctly classified, (middle) wrongly classified as FC, (right) wrongly classified as indeterminate, stratified by age of less than or greater than 1 year. FC, febrile control; KD, Kawasaki disease.




Figure 5. . Performance of the two-step algorithm for classification of patients with KD and FCs stratified by number of KD principal clinical criteria. FCs, febrile controls; KD, Kawasaki disease; NPV, negative positive value; PPV, positive predictive value. A. 2X2 tables; B. Predictive performance comparison.

Characteristics	Taiwan Single Center Cohort		
	KD (n=418)	FC (n=259)	<i>p</i> -Value
Age, years, median (IQR <sup>a</sup> )	1.3 (0.7, 2.4)	1.0 (0.6, 4.6)	0.03
Males, n (%)	253 (60.5)	138 (53.3)	0.06
<b>Number of KD criteria met, n (%)</b>			
≤3	50 (12.0)	217 (83.8)	
4 or 5	368 (88.0)	42 (16.2)	

Table 1. Demographic characteristics of the testing cohort in Taiwan.

	Diagnosis, n (%)	Validation cohort (n = 258)
Bacterial infections	Cellulitis and abscess of leg, except foot	6 (2.3)
	Unspecified local infection of skin and subcutaneous tissue	6 (2.3)
	Cellulitis of buttock	5 (1.9)
	Cellulitis of unspecified orbit	3 (1.2)
	Peritonsillar abscess	3 (1.2)
	Cellulitis and abscess of finger, unspecified	2 (0.8)
	Cellulitis and abscess of hand, except fingers and thumb	2 (0.8)
	Streptococcal sore throat	1 (0.4)
	Scarlet fever	1 (0.4)
	Cellulitis and abscess of upper arm and forearm	1 (0.4)
	Cellulitis and abscess of foot, except toes	1 (0.4)
Either bacterial or virus infection	Neonatal conjunctivitis and dacryocystitis	1 (0.4)
	Chagas disease without mention of organ involvement	1 (0.4)
	Acute tonsillitis, unspecified	61 (23.6)
	Acute pharyngitis, unspecified	52 (20.2)
	Acute lymphadenitis	3 (1.2)
Others/Unknown	Acute nasopharyngitis	1 (0.4)
	Pharyngoconjunctival fever	1 (0.4)
	Unknown	39 (15.1)
	Urticaria, unspecified	4 (1.6)
	Lymphangioma, any site	1 (0.4)
	Contact dermatitis and other eczema, unspecified cause	1 (0.4)
	Allergic urticaria	1 (0.4)
Rash and other nonspecific skin eruption	1 (0.4)	
Viral infections	Other specified viral exanthemata	24 (9.3)
	Herpangina	11 (4.3)
	Hand, foot, and mouth disease	8 (3.1)
	Influenza with other respiratory manifestations	6 (2.3)
	Herpetic gingivostomatitis	5 (1.9)
	Influenza with pneumonia	3 (1.2)
	Adenoviral pneumonia	1 (0.4)
	Viral exanthem, unspecified	1 (0.4)
	Infectious mononucleosis	1 (0.4)

Table 2. The final diagnosis of the febrile illness controls.

Clinical signs, n (%)	KD principal clinical criteria								
	≤2			3			≥4		
	KD n=14	FC n=158	<i>p</i> value	KD n=36	FC n=59	<i>p</i> value	KD n=368	FC n=42	<i>p</i> value
Oral and pharyngeal changes	4 (28.6)	135 (85.4)	< 0.001	27 (75)	51 (86.4)	0.158	357 (97)	37 (88.1)	0.017
Conjunctival injection	10 (71.4)	5 (3.2)	< 0.001	29 (80.6)	12 (20.3)	< 0.001	357 (97)	34 (81)	< 0.001
Cervical lymph node (>1.5cm)	3 (21.4)	42 (26.6)	1	6 (16.7)	44 (74.6)	< 0.001	168 (45.7)	42 (100)	< 0.001
Extremity changes	3 (21.4)	9 (5.7)	0.061	19 (52.8)	21 (35.6)	0.1	355 (96.5)	22 (52.4)	< 0.001
Rash	8 (57.1)	102 (64.6)	0.58	27 (75)	49 (83.1)	0.341	353 (95.9)	40 (95.2)	0.689

Table 3A. Distribution of the clinical signs among KD and FC patients (count and percentage) in sub cohorts manifesting fewer than 2, 3 or ≥4 principal clinical criteria for KD. *p* value: Fisher's exact test. KD: Kawasaki disease; FC: febrile control.

	Clinical criteria *								
	≤2			3			≥4		
	KD n=14	FC n=158	p value	KD n=36	FC n=59	p value	KD n=368	FC n=42	p value
C-reactive protein, mg/dL	4.9 (1.3,7.2)	0.9 (0.3,3.1)	0.012	5.2 (2.7,10.3)	0.8 (0.4,4.7)	< 0.001	6.8 (3.8,12.7)	2.3 (0.7,4.7)	< 0.001
Eosinophils, %	4.7 (2.4,5.3)	0.3 (0,1.1)	< 0.001	2.4 (1,5)	0.7 (0.1,2.4)	< 0.001	2.5 (1,4.2)	1 (0,2.5)	< 0.001
Alanine aminotransferase, IU/L	35 (23.5,49)	20.5 (17,26)	0.014	32 (18.5,71.5)	20 (14,25)	0.002	38.5 (19,94.2)	29 (19.2,86.5)	0.398
Hemoglobin, g/dL	11.2 (9.8,11.8)	12 (11.2,12.9)	0.002	10.9 (10.2,11.6)	11.9 (11.1,12.9)	< 0.001	11.3 (10.5,11.9)	12.2 (11.5,12.8)	< 0.001
Lymphocyte, %	34 (29.7,46)	37.6 (22,50.2)	0.764	33.5 (27,44.1)	35.1 (21.1,51.4)	0.939	27 (19,39.1)	38.4 (27.1,51.9)	< 0.001
Monocyte, %	7 (5,10)	8.9 (6.5,10.8)	0.102	5 (3,7)	7.9 (6,10)	< 0.001	5.3 (4,7.1)	6 (4,2.8)	0.277
Mature neutrophil, %	50.6 (41.3,56)	49.6 (37.8,70.8)	0.664	49.7 (42.2,63.1)	54.9 (34.2,67.1)	0.979	62 (48,6,71)	50 (41,65)	< 0.001
Platelet counts, 10 <sup>3</sup> /mm <sup>3</sup>	367 (280,8,411)	216 (175,301)	< 0.001	382 (263,467.5)	258 (190.5,297)	< 0.001	318 (257,386.5)	296.5 (205.2,362)	0.042
White blood cell, 10 <sup>3</sup> /mm <sup>3</sup>	12.7 (10.3,17.8)	9.1 (4.9,13.3)	0.006	12.5 (10.4,15.2)	10.7 (6.5,14.3)	0.017	12.9 (10.5,16.1)	12.9 (10,16)	0.97

Table 3B. Univariable analysis of laboratory test variables in patients with KD and FCS who had fewer than two, three and at least four clinical criteria

Table 4A. Performance of the 2-step algorithm in Kawasaki disease patients and febrile controls stratified by age at onset and days of illness. There were 8 FC subjects missing age information at the first day of fever. .

Sub-cohorts	Sensitivity, % (95% CI)	Specificity, % (95% CI)	PPV, % (95% CI)	NPV, % (95% CI)	Indeterminate KD, % (95% CI)	Indeterminate FC, % (95% CI)
Age at onset <sup>a</sup>						
< 1 year (KD, n=157; FC, n=93)	93.3 (88.1-96.8)	94.5 (87.6-98.2)	96.6 (92.1-98.9)	89.6 (81.7-94.9)	4.5 (1.3-8.3)	2.2 (0.0-5.4)
≥ 1 year (KD, n=261; FC, n=158)	94.5 (90.9-96.9)	83.9 (77.1-89.3)	90.5 (86.3-93.8)	90.3 (84.2-94.6)	3.1 (1.1-5.4)	1.9 (0.0-4.4)
Illness days						
<8 (KD, n=327; FC, n=252)	93.7 (90.4-96.1)	89.1 (84.6-92.7)	91.6 (88.0-94.4)	91.7 (87.5-94.9)	3.7 (1.8-5.8)	1.6 (0.4-3.6)
8-10 (KD, n=91; FC, n=7)	95.5 (88.8-98.7)	40.0 (5.3-85.3)	96.6 (90.3-99.3)	33.3 (4.3-77.7)	3.3 (0.0-7.7)	28.6 (0.0-71.4)

<sup>a</sup>Age at the first day of fever

Table 4B. Comparison of ratio of median laboratory values in Kawasaki disease patients to that in febrile controls.

Variable	Ratio of median in Kawasaki disease patients to median in febrile controls	
	Illness days <8 (KD, n=327; FC, n=252)	Illness days 8-10 (KD, n=91; FC, n=7)
C-reactive protein	3.022	1.003
Eosinophils	2.794	3.105
Alanine aminotransferase	2.659	0.82
Hemoglobin	0.92	0.933
Lymphocyte	0.825	0.872
Monocyte	0.698	1.001
Mature neutrophil	1.133	1.022
Platelet counts	1.299	1.127
White blood cell	1.234	0.976

Coronary artery status by echocardiogram, n	KD, correctly classified	KD, classified indeterminate	KD, misclassified
<b>Normal</b> (RCA&LAD always <2.5)	309	10	12
<b>Dilated</b> (Z score (RCA or LAD) $\geq 2.5$ , and resolve in 8 weeks)	30	0	1
<b>Aneurysm</b> (Z score $\geq 5$ , or dilated segment $> 1.5$ )	8	0	0
<b>Others</b>			
Z score (RCA or LAD) $\geq 2.5$ , but not resolve in 8 weeks	12	0	0
Z score (RCA or LAD) $\geq 2.5$ , but had no data after 8 weeks	1	0	0
Data missing	10	0	0
No 2D echo	9	5	11

\* RCA: Right coronary artery; LAD: Left anterior descending. 2D echocardiography: 2D echo.

Table 5. Performance of the two-step algorithm in relation to echocardiogram results.

Table 6. Clinical variables of Kawasaki disease patients and febrile controls in the 2020 US multicenter, 2016 US single-center and current Asia single-center validation studies.

Variable	Kawasaki disease patients			Febrile controls		
	Multicenter, n=1059	Single-center, n=268	Taiwan-center, n=418	Multicenter, n=282	Single-center, n=161	Taiwan-center, n=259
Cervical lymph node >1.5 cm, n (%)	349 (33.0)	88 (32.8)	177 (42.3)	55 (19.5)	41 (25.5)	128 (49.4)
Rash, n (%)	962 (90.8)	256 (95.5)	388 (92.8)	200 (70.9)	102 (63.4)	191 (73.7)
Conjunctival injection, n (%)	991 (93.6)	255 (95.1)	396 (94.7)	166 (58.9)	71 (44.1)	51 (19.7)
Extremity changes, n (%)	812 (76.7)	217 (81.0)	377 (90.2)	54 (19.1)	30 (18.6)	52 (20.1)
Oropharyngeal changes, n (%)	956 (90.3)	243 (90.7)	388 (92.8)	132 (46.8)	78 (48.4)	223 (86.1)
Days of illness, median (IQR <sup>a</sup> )	6.0 (5.0,7.0)	6.0 (4.0,7.0)	6.0 (5.0,7.0)	5.0 (4.0,7.0)	5.0 (3.0,6.0)	2.0 (1.0,3.0)